Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation

Sakellariou, G; Anastasilakis, Athanasios D.; Bisbinas, Ilias; Oikonomou, Dimitrios; Gerou, Spyridon; Polyzos, Stergios A.; Sayegh, Fares E.

doi:10.1093/rheumatology/keu425

Cited by 30 publications

(23 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because sclerostin was low before the syndesomphytes appeared, the data suggest that low sclerostin increased the susceptibility for syndesmophyte formation (14). This is consistent with the results of a more recent study by Sakellariou, et al, showing that sclerostin expression is blunted in patients with AS and patients with low serum sclerostin are more likely to develop ankyloses (37). This data showing low osteocyte sclerostin expression only in joint diseases with bony spurs (AS and OA) suggest low sclerostin as a biomarker for predicting the structural progression of bony disease (14).…”

Section: Sclerostin In Osteoarthritis and Rheumatic Joint Diseasesupporting

confidence: 92%

“…AS predominantly affects axial joints and interverterbral spaces, with bone deposition occurring at the inflamed entheses causing syndesmophyte formation, fused facet joints, back pain, and reduced mobility (14, 37). Analysis of zygapophyseal (ZA) joints obtained from AS patients, as well as healthy control tissue in the German SA Inception cohort study, showed that sclerostin positive osteocytes were significantly reduced in AS patient tissue (15% versus 53% positive in controls).…”

Section: Sclerostin In Osteoarthritis and Rheumatic Joint Diseasementioning

confidence: 99%

See 1 more Smart Citation

Sclerostin expression and functions beyond the osteocyte

Weivoda

Youssef

Oursler

2017

Bone

103

View full text Add to dashboard Cite

Sclerostin, the product of the SOST gene, is a secreted inhibitor of Wnt signaling that is produced by osteocytes to regulate bone formation. While it is often considered an osteocyte-specific protein, SOST expression has been reported in numerous other cell types, including hypertrophic chondrocytes and cementocytes. Of interest, SOST/sclerostin expression is altered in certain pathogenic conditions, including osteoarthritis and rheumatic joint disease, and it is unclear whether sclerostin plays a protective role or whether sclerostin may mediate disease pathogenesis. Therefore, as anti-sclerostin antibodies are being developed for the treatment of osteoporosis, it is important to understand the functions of sclerostin beyond the regulation of bone formation.

show abstract

Section: Sclerostin In Osteoarthritis and Rheumatic Joint Diseasesupporting

confidence: 92%

Section: Sclerostin In Osteoarthritis and Rheumatic Joint Diseasementioning

confidence: 99%

Sclerostin expression and functions beyond the osteocyte

Weivoda

Youssef

Oursler

2017

Bone

103

View full text Add to dashboard Cite

show abstract

“…The negative association between periostin and sclerostin levels, shown in this study, is supportive to the previous report of the suppressive effect of periostin on sclerostin expression in osteocytes (10). We have previously reported similar periostin levels in women with postmenopausal osteoporosis and controls (11), but lower in patients with ankylosing spondylitis than controls (12). However, these metabolic bone diseases are pathophysiologically different from JPD.…”

Section: Discussionmentioning

confidence: 62%

Periostin and sclerostin levels in juvenile Paget�s disease

Polyzos

Makras

Anastasilakis

et al. 2017

ccmbm

View full text Add to dashboard Cite

SummaryJuvenile Paget's disease (JPD) is a rare, autosomal recessive disorder featuring markedly increased serum alkaline phosphatase activity, indicative of greatly accelerated bone turnover throughout the skeleton. The main aim of this study was to evaluate circulating periostin and sclerostin levels in two adult patients with mild JPD (due to "Balkan" mutation). We measured periostin and sclerostin levels in a previously described woman and a newly diagnosed man with JPD, and 10 apparently healthy individuals, matched (1:5) to JPD patients for gender, age and body mass index. Sclerostin levels were similar between JPD patients and controls. Periostin levels were about 2.5 times higher in JPD patients. Periostin and sclerostin levels were negatively correlated (rs= -0.63; p=0.03). In conclusion, a trend towards higher periostin levels was observed in JPD patients, whereas sclerostin levels were similar to controls.

show abstract

“…High serum periostin is independently associated with increased fracture risk in postmenopausal women, 6, 7 whereas high periostin has been associated with disease activity, systemic inflammation and bone damage in ankylosing spondylitis. 8 Periostin expression is upregulated by several members of the transforming growth factor-β superfamily, including activin-A, which has been found to be elevated in MM by our group. 9 Recent clinical evidence suggests that periostin stimulates metastatic growth by promoting cancer cell survival, invasion and angiogenesis in several cancers.…”

Section: Introductionmentioning

confidence: 63%

High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma

Terpos

Christoulas

Kastritis

et al. 2016

Blood Cancer Journal

View full text Add to dashboard Cite

Periostin is an extracellular matrix protein that is implicated in the biology of normal bone remodeling and in different cancer cell growth and metastasis. However, there is no information on the role of periostin in multiple myeloma (MM). Thus, we evaluated periostin in six myeloma cell lines in vitro; in the bone marrow plasma and serum of 105 newly diagnosed symptomatic MM (NDMM) patients and in the serum of 23 monoclonal gammopathy of undetermined significance (MGUS), 33 smoldering MM (SMM) patients, 30 patients at the plateau phase post-first-line therapy, 30 patients at first relapse and 30 healthy controls. We found high levels of periostin in the supernatants of myeloma cell lines compared with ovarian cancer cell lines that were not influenced by the incubation with the stromal cell line HS5. In NDMM patients the bone marrow plasma periostin was almost fourfold higher compared with the serum levels of periostin and correlated with the presence of fractures and of diffuse magnetic resonance imaging pattern of marrow infiltration. Serum periostin was elevated in NDMM patients compared with healthy controls, MGUS and SMM patients and correlated with advanced disease stage, high lactate dehydrogenase, increased activin-A, increased bone resorption and reduced bone formation. Patients at first relapse had also elevated periostin compared with healthy controls, MGUS and SMM patients, while even patients at the plateau phase had elevated serum periostin compared with healthy controls. These results support an important role of periostin in the biology of myeloma and reveal periostin as a possible target for the development of antimyeloma drugs.

show abstract

Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation

Cited by 30 publications

References 41 publications

Sclerostin expression and functions beyond the osteocyte

Sclerostin expression and functions beyond the osteocyte

Periostin and sclerostin levels in juvenile Paget�s disease

High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma

Contact Info

Product

Resources

About